| 000 | 03397nlm1a2200457 4500 | ||
|---|---|---|---|
| 001 | 668451 | ||
| 005 | 20231030042149.0 | ||
| 035 | _a(RuTPU)RU\TPU\network\39676 | ||
| 035 | _aRU\TPU\network\34148 | ||
| 090 | _a668451 | ||
| 100 | _a20221205a2022 k y0engy50 ba | ||
| 101 | 0 | _aeng | |
| 102 | _aAE | ||
| 135 | _adrcn ---uucaa | ||
| 181 | 0 | _ai | |
| 182 | 0 | _ab | |
| 200 | 1 |
_aAntibacterial and Phagocytic Properties of a Novel Silver-Interferon Complex _fE. V. Plotnikov, V. M. Plotnikov |
|
| 203 |
_aText _celectronic |
||
| 300 | _aTitle screen | ||
| 330 | _aBackground: Developing new antibacterial and antiviral drugs are considered a significant issue due to the emergence and spread of resistant strains of microorganisms. The COVID-19 pandemic has dramatically increased the need for new broad-spectrum anti-infective agents. Objective: This experimental study aimed to investigate the antibacterial and phagocytic properties of silver-interferon preparation. The combination of properties of complex drugs makes them promising for treating drug-resistant infections and bacterial complications of viral diseases. Methods: The antibacterial effect of the silver-interferon platform was investigated by agar diffusion and serial dilution methods. The drug's effect on the functional activity of phagocytes was studied on human neutrophils in a Staphylococcus aureus uptake test. Results: Investigations have shown that the silver-interferon complex possesses a bactericidal mechanism of action against tested bacterial strains, including Streptococcus pneumonia, Salmonella enteritidis, Staphylococcus aureus, Escherichia coli. Streptococcus pneumonia was the most susceptible bacterial target for the tested complex, with a growth inhibition zone of 12±0.6 mm and a minimal bactericidal concentration of 0.08 mg/ml. A slight stimulating action of the drug in relation to the activity of phagocytes was revealed. Conclusion: Silver-interferon has proved as a prospective anti-infective drug with a wide range of activities. | ||
| 330 | _a[References: 27 tit.] | ||
| 333 | _aРежим доступа: по договору с организацией-держателем ресурса | ||
| 461 | _tAnti-Infective Agents | ||
| 463 |
_tVol. 20, iss. 4 _v[P. 11-15] _d2022 |
||
| 610 | 1 | _aэлектронный ресурс | |
| 610 | 1 | _aтруды учёных ТПУ | |
| 610 | 1 | _asilver | |
| 610 | 1 | _aantibacterial activity | |
| 610 | 1 | _aimmune-stimulation | |
| 610 | 1 | _ainterferon | |
| 610 | 1 | _anosocomial infections | |
| 610 | 1 | _aphagocytosis | |
| 610 | 1 | _aантибактериальная активность | |
| 610 | 1 | _aинтерфероны | |
| 610 | 1 | _aфагоцитоз | |
| 700 | 1 |
_aPlotnikov _bE. V. _cchemist _cAssociate Professor of Tomsk Polytechnic University, Candidate of Chemical Sciences _f1983- _gEvgeny Vladimirovich _2stltpush _3(RuTPU)RU\TPU\pers\32469 |
|
| 701 | 1 |
_aPlotnikov _bV. M. _gVladimir Mikhaylovich |
|
| 712 | 0 | 2 |
_aНациональный исследовательский Томский политехнический университет _bИсследовательская школа химических и биомедицинских технологий _c(2017- ) _h8120 _2stltpush _3(RuTPU)RU\TPU\col\23537 |
| 801 | 2 |
_aRU _b63413507 _c20221205 _gRCR |
|
| 856 | 4 | _uhttps://doi.org/10.2174/2211352520666220404143923 | |
| 942 | _cCF | ||